Evaluate Pembrolizumab (Keytruda): CADTH Reimbursement Suggestion: Indicator: Together with chemotherapy, to the procedure of adult people with regionally recurrent unresectable or metastatic triple-destructive breast most cancers who may have not been given prior chemotherapy for metastatic ailment and whose tumours Categorical programmed mobile d